Inhibikase Therapeutics, Inc. Q4 FY2022 earnings call

• 2022 was a year of advancing lead asset IkT-148009 in clinic and validating mechanisms. FDA lifted hold on Parkinson's program in January and on MSA program in March. 501 bioequivalent study for IkT-001Pro completed 3 of 4 dose escalation cohorts. - Grant revenue decreased to $0.1 million in 2022 from $3.1 million in 2021 due to shift to advancing clinical trials. R&D expenses increased to $12 million in 2022 from $11.4 million in 2021. SG&A expenses decreased to $6.2 million in 2022 from $6.5 million in 2021. Net loss was $18.1 million in 2022 compared to $14.8 million in 2021. Cash, cash equivalents, and marketable securities as of Dec 31, 2022 were ~$23.1 million.

There are no specific product segments with financial performance details provided as the company's focus is on clinical development of therapeutics rather than traditional product segments with revenue contribution percentages.

• Existing cash, cash equivalents, and marketable securities are expected to fund operations into the fourth quarter of 2024. - 2023 is viewed as a year of clinical execution with plans to share additional clinical updates for IkT-148009 as the 201 trial enrolls patients, advance preclinical efforts in MSA, and complete the 501 bioequivalent study for IkT-001Pro.

• Risks associated with the company's business, including potential differences between actual results and forward-looking statements due to uncertainties. - Risks related to clinical trial progress, regulatory holds (though some holds were lifted, there are ongoing risks in clinical development).

Q: A: Q: A: No questions were posed during the call as indicated by the operator